Li Y, Wang Z, Kong M, Yong Y, Yang X, Liu C
Front Pharmacol. 2024; 15:1447605.
PMID: 39228516
PMC: 11368878.
DOI: 10.3389/fphar.2024.1447605.
Simon P, Lorinczi B, Szatmari I
Int J Mol Sci. 2024; 25(13).
PMID: 39000077
PMC: 11241777.
DOI: 10.3390/ijms25136966.
Turzo S, Hantz E, Lindert S
QRB Discov. 2023; 3:e14.
PMID: 37529294
PMC: 10392679.
DOI: 10.1017/qrd.2022.12.
Chang Y, Hawkins B, Du J, Groundwater P, Hibbs D, Lai F
Pharmaceutics. 2023; 15(1).
PMID: 36678678
PMC: 9867171.
DOI: 10.3390/pharmaceutics15010049.
Feng M, Heinzelmann G, Gilson M
Sci Rep. 2022; 12(1):13640.
PMID: 35948614
PMC: 9365818.
DOI: 10.1038/s41598-022-17480-w.
Investigation on penetration of saffron components through lipid bilayer bound to spike protein of SARS-CoV-2 using steered molecular dynamics simulation.
Kordzadeh A, Ramazani Saadatabadi A, Hadi A
Heliyon. 2020; 6(12):e05681.
PMID: 33344790
PMC: 7733551.
DOI: 10.1016/j.heliyon.2020.e05681.
Synthesis and characterization of 1,2,4-triazolo[1,5-a]pyrimidine-2-carboxamide-based compounds targeting the PA-PB1 interface of influenza A virus polymerase.
Massari S, Bertagnin C, Pismataro M, Donnadio A, Nannetti G, Felicetti T
Eur J Med Chem. 2020; 209:112944.
PMID: 33328103
PMC: 7561591.
DOI: 10.1016/j.ejmech.2020.112944.
New fluorescence-based high-throughput screening assay for small molecule inhibitors of tyrosyl-DNA phosphodiesterase 2 (TDP2).
Ribeiro C, Kankanala J, Shi K, Kurahashi K, Kiselev E, Ravji A
Eur J Pharm Sci. 2018; 118:67-79.
PMID: 29574079
PMC: 6370590.
DOI: 10.1016/j.ejps.2018.03.021.
Design, synthesis, and biological evaluation of 3-vinyl-quinoxalin-2(1H)-one derivatives as novel antitumor inhibitors of FGFR1.
Liu Z, Yu S, Chen D, Shen G, Wang Y, Hou L
Drug Des Devel Ther. 2016; 10:1489-500.
PMID: 27217720
PMC: 4861610.
DOI: 10.2147/DDDT.S88587.
Using docking and alchemical free energy approach to determine the binding mechanism of eEF2K inhibitors and prioritizing the compound synthesis.
Wang Q, Edupuganti R, Tavares C, Dalby K, Ren P
Front Mol Biosci. 2015; 2:9.
PMID: 25988177
PMC: 4429643.
DOI: 10.3389/fmolb.2015.00009.
Molecular modeling study of the induced-fit effect on kinase inhibition: the case of fibroblast growth factor receptor 3 (FGFR3).
Li Y, Delamar M, Busca P, Prestat G, Le Corre L, Legeai-Mallet L
J Comput Aided Mol Des. 2015; 29(7):619-41.
PMID: 25808135
DOI: 10.1007/s10822-015-9841-8.
Illuminating the molecular mechanisms of tyrosine kinase inhibitor resistance for the FGFR1 gatekeeper mutation: the Achilles' heel of targeted therapy.
Sohl C, Ryan M, Luo B, Frey K, Anderson K
ACS Chem Biol. 2015; 10(5):1319-29.
PMID: 25686244
PMC: 4533833.
DOI: 10.1021/acschembio.5b00014.
Synthesis and biological evaluation of novel indole-2-one and 7-aza-2-oxindole derivatives as anti-inflammatory agents.
Chen G, Jiang L, Dong L, Wang Z, Xu F, Ding T
Drug Des Devel Ther. 2014; 8:1869-92.
PMID: 25378906
PMC: 4207570.
DOI: 10.2147/DDDT.S65997.
Distinguishing binders from false positives by free energy calculations: fragment screening against the flap site of HIV protease.
Deng N, Forli S, He P, Perryman A, Wickstrom L, Vijayan R
J Phys Chem B. 2014; 119(3):976-88.
PMID: 25189630
PMC: 4306491.
DOI: 10.1021/jp506376z.
Identification and validation of novel PERK inhibitors.
Wang Q, Park J, Devkota A, Cho E, Dalby K, Ren P
J Chem Inf Model. 2014; 54(5):1467-75.
PMID: 24745945
PMC: 4038368.
DOI: 10.1021/ci500114r.
Computational methods in drug discovery.
Sliwoski G, Kothiwale S, Meiler J, Lowe Jr E
Pharmacol Rev. 2014; 66(1):334-95.
PMID: 24381236
PMC: 3880464.
DOI: 10.1124/pr.112.007336.
Ligand pose and orientational sampling in molecular docking.
Coleman R, Carchia M, Sterling T, Irwin J, Shoichet B
PLoS One. 2013; 8(10):e75992.
PMID: 24098414
PMC: 3787967.
DOI: 10.1371/journal.pone.0075992.
In silico identification of EGFR-T790M inhibitors with novel scaffolds: start with extraction of common features.
Xiang M, Lei K, Fan W, Lin Y, He G, Yang M
Drug Des Devel Ther. 2013; 7:789-839.
PMID: 23990708
PMC: 3748928.
DOI: 10.2147/DDDT.S41305.
Parallel screening of wild-type and drug-resistant targets for anti-resistance neuraminidase inhibitors.
Hsu K, Hung H, Horng J, Fang M, Chang C, Li L
PLoS One. 2013; 8(2):e56704.
PMID: 23437217
PMC: 3577712.
DOI: 10.1371/journal.pone.0056704.
Design, synthesis, and antiviral activity of entry inhibitors that target the CD4-binding site of HIV-1.
Curreli F, Choudhury S, Pyatkin I, Zagorodnikov V, Bulay A, Altieri A
J Med Chem. 2012; 55(10):4764-75.
PMID: 22524483
PMC: 3372086.
DOI: 10.1021/jm3002247.